Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Baxter
McKesson
Moodys
Medtronic

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR ALIMTA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Alimta

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00022646 ↗ Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 2 2001-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or metastatic non-small cell lung cancer.
NCT00022646 ↗ Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed Alliance for Clinical Trials in Oncology Phase 2 2001-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or metastatic non-small cell lung cancer.
NCT00034463 ↗ ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer Completed Eli Lilly and Company Phase 1 1969-12-31 This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
NCT00034502 ↗ A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer. Completed Eli Lilly and Company Phase 1/Phase 2 1969-12-31 This is a non-randomized study in patients who have received prior 5-FU therapy for colorectal cancer. The objective of this trial is to establish a maximum tolerated dose of ALIMTA and irinotecan given in combination as well as to assess the safety and efficacy of this combination for patients with locally advanced or metastatic colorectal cancer. ALIMTA and irinotecan will be given every 21 days.
NCT00034593 ↗ A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium Completed Eli Lilly and Company Phase 2 1969-12-31 Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
NCT00034606 ↗ Comparing 3 Schedules of Alimta Plus Gemzar Completed Eli Lilly and Company Phase 2 1969-12-31 The purpose of the study is to measure tumor response rates for three schedules of Alimta(LY231514) in combination with gemcitabine in patients with locally advanced or metastatic non small cell lung cancer who have received no prior chemotherapy regimen.
NCT00034619 ↗ A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer. Completed Eli Lilly and Company Phase 2 1969-12-31 The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Alimta

Condition Name

Condition Name for Alimta
Intervention Trials
Non-Small Cell Lung Cancer 50
Non Small Cell Lung Cancer 32
Lung Cancer 32
Carcinoma, Non-Small-Cell Lung 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Alimta
Intervention Trials
Carcinoma, Non-Small-Cell Lung 191
Lung Neoplasms 181
Mesothelioma 23
Carcinoma 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Alimta

Trials by Country

Trials by Country for Alimta
Location Trials
China 87
United Kingdom 77
Spain 65
Italy 60
Canada 53
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Alimta
Location Trials
California 69
Pennsylvania 63
Florida 62
Texas 62
Ohio 61
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Alimta

Clinical Trial Phase

Clinical Trial Phase for Alimta
Clinical Trial Phase Trials
Phase 4 6
Phase 3 49
Phase 2 192
[disabled in preview] 82
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Alimta
Clinical Trial Phase Trials
Completed 196
Terminated 54
Recruiting 26
[disabled in preview] 53
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Alimta

Sponsor Name

Sponsor Name for Alimta
Sponsor Trials
Eli Lilly and Company 145
National Cancer Institute (NCI) 56
Merck Sharp & Dohme Corp. 14
[disabled in preview] 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Alimta
Sponsor Trials
Industry 256
Other 238
NIH 56
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Merck
Express Scripts
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.